Sativa, indica and hybrid are common retail descriptions. They do not reliably tell a patient whether a particular product will improve sleep, relieve pain or make them more alert. The botanical history of the words and their use on today's menus are different questions.
Our earlier article challenged a simple sativa/indica divide but then suggested that expectation and aroma could predict the experience. That conclusion also went beyond the evidence. This revision separates labels, measured composition and clinical effects.
Why the familiar day-and-night rule is limited
Menus often associate sativa with daytime energy and indica with evening relaxation. Repeating that convention does not establish a treatment effect. Plants sold under the same label can differ, and an experience depends on more than the name on a package.
In a 2021 study of cannabis labels, genetics and chemistry, the broad sativa/indica labels poorly captured overall genetic and chemical variation. The researchers did find associations with particular terpenes and terpene-synthase genes. It is therefore inaccurate to summarise the result as “no relationship with chemistry.” The study did not test which label treats a patient's symptoms. Original study: cannabis labelling and terpene-synthase genes.
A strain name is also a label
A 2022 analysis of commercial US cannabis data found that common retail labels did not consistently represent the measured chemical diversity. Strain names varied in how chemically consistent they were. These are findings about samples and labelling in that market, not proof that every named product everywhere has the same problem. Original study of commercial cannabis chemical diversity.
When evaluating a product, ask for information about the actual batch. A generic description copied from a strain database cannot substitute for its label or report. A claimed percentage should identify what was measured and in which sample.
Keep three questions separate
| Question | Relevant information |
|---|---|
| How is this product described? | Its retail label, strain name and sensory description |
| What was measured in it? | Product identity and a matching laboratory report |
| Is it appropriate for my treatment? | Clinical assessment and evidence relevant to the preparation and condition |
No single row answers all three. A composition report can be useful without guaranteeing a benefit. An aroma preference can be real without identifying a safe treatment.
Expectation does not give control over impairment
Personal accounts can help describe an experience, but they do not show that someone can make cannabis energising or sedating simply by deciding how they want to feel. The earlier claim that it would improve a workout was unsupported and has been removed.
Neither a daytime label nor feeling alert establishes fitness to drive or perform hazardous work. Bring questions about impairment, other medicines and daily responsibilities to the treating professional. See our THC and CBD comparison for the distinction between composition and medical suitability.
A better way to ask for information
Instead of “Which indica cures insomnia?”, ask what preparation is being proposed, what evidence supports it for the problem under assessment, what unwanted effects matter and when treatment will be reviewed. Ask the supplier to explain product and batch information without assigning a diagnosis from a strain name.
For aroma descriptions, read cannabis aroma and sensory limits. For treatment questions, read cannabis and sleep evidence. Those are separate topics because liking a smell and obtaining a clinical benefit are different outcomes.
Corrected 6 September 2026. Encoding damage, unsupported effect predictions and an inaccurate summary of the 2021 study have been corrected.
